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A Biocatalytic Approach Towards the Stereoselective Synthesis of 
Protected Inositols  
L. H. Sayer,
a
 G. J. Florence
a*
 and T. K. Smith
a* 
A biocatalytic flow system utilising Trypanosoma brucei L-myo-inositol 1-phosphate synthase has been developed to 
prepare significant quantities of L-myo-inositol 1-phosphate.  Using this highly valuable biochemical, we have 
demonstrated its utility as a viable starting material in a drastically improved and shortened synthesis of a key 
intermediate in the synthesis of the biologically important myo-inositol derivatives.  This biotransformation allows rapid 
and stereospecific inositol derivatives to be synthesized, on a larger scale than ever before.  
Introduction 
myo-Inositol is ubiquitous in nature and can be found 
as the structural core of a diverse range of biological 
metabolites, including inositol phosphates, 
phosphatidylinositols and their phosphates, 
glycosylphosphatidylinositol (GPI) anchors
1
 and 
mycothiol
2
.  Many of these compounds have important 
and fundamental biological functions, including cellular 
signalling,
3
 protein anchoring
1
 and pathogen virulence.
4
   
Given their essential function in living systems, they 
have been the focus of significant research in both 
academia and industry. 
The stereo-controlled synthesis of protected myo-
inositol derivatives presents a number of obstacles and 
challenges, often requiring lengthy synthetic 
sequences, which suffer significant material loss as a 
consequence.
5
 myo-Inositol chemistry faces the 
regioselectivity issues associated with classical 
carbohydrate chemistry, but the situation is further 
complicated by the inherent symmetry of the myo-
inositol core and the requirement to break the 
symmetry plane to access the desired enantiomer.  In 
order to overcome the complex enantioselectivity 
issues it is generally necessary to perform a chemical or 
enzymatic resolution, which further detriments the 
yield of synthetic routes.  
The eukaryotic de novo biosynthesis of myo-inositol (3), 
shown in Scheme 1, involves the sequential action of 
two enzymes: L-myo-inositol 1-phosphate synthase 
(INO1, E.C.5.5.1.4) and myo-inositol monophosphatase 
(IMPase, E.C.3.1.3.25).
6
  The rate-limiting step of this 
process is the conversion of D-glucose 6-phosphate 
(GP, 1) to L-myo-inositol 1-phosphate (IP, 2) by INO1, 
which employs nicotinamide adenine dinucleotide 
(NAD
+
) as a cofactor. A biocatalytic approach using 
INO1 would facilitate direct access to enantiopure IP 
(2).7  This is an attractive target due to its high 
commercial value (€196 mg
-1
, Cayman Chemical), but 
also due to the potential for its use as a starting point 
in the syntheses of numerous myo-inositol derivatives 
with significantly reduced step counts.  Using selective 
protection strategies we envisaged the ability to gain 
access to any protection pattern around the myo-
inositol core.  A clear advantage of the present 
approach would be the removal of bottleneck 
resolution step (50% max yield) as IP (2) is produced 
directly and would provide a unique and previously 
unavailable chiral pool starting material. However, the 
use of IP for chemical synthesis is not without challenge 
and will require an extensive study of protecting group 
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conditions compatible with the phosphate or it’s 
corresponding phosphate ester.  
In considering the use of an INO1 enzyme for 
biocatalysis we identified several key facets.  Firstly, the 
cofactor, NAD
+
, is both reduced and reoxidised within 
the reaction, so there is no net change.  This allows a 
much lower amount of NAD
+
 to be used which would 
be the most expensive component of the system, 
lowering the potential need for co-factor regeneration 
in situ. The starting material, GP (1), is relatively 
inexpensive (€29 g
-1
, Sigma Aldrich) compared to the IP 
product. Once established as viable, this system should 
be able to incorporate a commercial hexokinase 
upstream to access GP (1) from glucose.  Biocatalytic 
production of IP (2) has previously been accomplished 
using whole cell fermentation of recombinant S. 
cerevisiae INO1
8
 and isolated recombinant INO1 
enzyme preparations.
9,10
 This work clearly 
demonstrates the potential for the biocatalytic 
production of IP, however within an industrial setting 
these methods may fail to provide an efficient and 
economical route to IP (2). 
The protozoan parasite Trypanosoma brucei relies upon 
the de novo synthesis of myo-inositol for its 
survival.
11,12
  The T. brucei INO1 (TbINO1) has been 
cloned and overexpressed in Escherichia coli using a 
pBAD TA vector, which encodes a C-terminal hexa-His 
tag.
11
  The recombinant TbINO1 protein was shown to 
be catalytically active as part of a coupled assay 
developed for a drug discovery programme, whereby 
the inhibition of TbINO1 activity was assessed by the 
phosphate released by produced IP via an IMPase. 
Saturation kinetic studies showed TbINO1 to have an 
apparent Km of 0.58 mM and Vmax of 0.25 mole hour
-1
 
with respect to [GP (1)]. The specific activity of 
recombinant TbINO1 was determined to be 756 U mg
-1
 
at 37 °C where 1 U is the amount of enzyme catalysing 
the formation of 1 nmole of IP (2) per minute at 37 °C.
11
  
The specific activity of recombinant TbINO1 is 
approximately 10-fold higher than that of human 
recombinant INO1 (70 U mg
-1
).  The protein proved 
relatively stable operating at an optimum temperature 
 
Scheme 1 – Biosynthesis of myo-inositol (3). 
of 37 °C. The reaction was conducted on a <1 mg scale 
in tris(hydroxymethyl)aminoethane acetate buffer at 
pH 8.0 and 37 °C.  The reaction solution contained 
5 mM GP (1), 1 mM NAD
+
, 2 mM ammonium acetate, 1 
mM dithiothreitol (DTT) and 5 μg of TbINO1 in a total 
volume of 150 μL. Enzyme activity was dependent upon 
NH4
+
 ions, with activity reduced to 10 U mg
-1
 in their 
absence.  TbINO1 has been shown to furnish complete 
conversion to IP (2), which is important when 
considering the optimization and scale up of this 
process.  It not only increases efficiency, but also avoids 
potential difficulties in the separation of IP (2) from any 
remaining GP (1) due to their similarly high polarity.  
TbINO1, therefore, looks like an ideal candidate for use 
in the biocatalytic production of IP (2).   
Results and discussion 
TbINO1 Expression, Purification and Assay 
Recombinant TbINO1 was expressed as previously 
detailed
14
 and purified by Ni
2+
-affinity chromatography, 
eluting with an increasing gradient of imidazole in 
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20 mM ammonium bicarbonate (pH 8.5) and 250 mM 
NaCl.  The protein was dialysed against a solution of 
20 mM ammonium bicarbonate (pH 8.5), 50 mM NaCl 
and 5 mM DTT, and stored with 20 % glycerol at -80 °C.  
This process yielded the recombinant TbINO1 enzyme 
in a yield of 75 mg L
-1 
of culture broth.  Conversion of 
TbINO1 reactions was determined colourimetrically, 
using the established IMPase assay.
11
 
 
Batch Scale and Flow Optimisation 
In assessing the original TbINO1 assay conditions for 
batch reactions,
14
 we sought to exchange the buffer 
from tris(hydroxymethyl)aminoethane acetate to 
ammonium bicarbonate This change facilitates the 
direct isolation of IP due to the volatility of ammonium 
bicarbonate, while also reducing the number of 
components in the reaction solution but maintaining 
ammonium ion concentration. Initial experiments were 
run in the ammonium bicarbonate buffer on a 0.4 mg 
scale in a total volume of 150 μL.  Optimisation to a 
conversion of >95 % was achieved with the reaction 
containing 10 mM GP (1), 2 mM NAD+, 1 mM DTT, 
50 mM ammonium bicarbonate (pH 8.5) and 87 μg 
TbINO1 at 37 °C overnight. Conversion was determined 
by an IMPase assay using the malachite green method 
of Itaya and Ui to determine free phosphate released.
15
 
Scaling up to 10 mg scale was accomplished by 
increasing TbINO1 to 300 μg and the total reaction 
volume to 600 μL and provided quantitative 
conversions. The concentrations of NAD
+
, DTT and 
ammonium bicarbonate (pH 8.5) were maintained at 
the original levels. 
Attempts to further increase the scale of the batch 
reaction beyond a 10 mg scale proved less satisfactory.  
On 100 mg GP (1) scale a maximum conversion of 76% 
was achieved after six days using a reaction system 
containing 4 mM NAD
+
, 1 mM DTT, 50 mM ammonium 
bicarbonate (pH 8.5) and 300 μg TbINO1 in a total 
volume of 1 mL.  In assessing the various factors that 
prevented full conversion, we observed the yellowing 
of the reaction mixture to be consistent with the 
breakdown of NAD
+
 over extended time periods in 
basic reaction medium.
16
 Furthermore, additional NAD
+
 
dosing did not restore enzyme activity and no further 
GP conversion was observed. Furthermore, the abrupt 
halt to reaction progress after six days coincided with 
precipitation of denatured TbINO1. Thus for the batch 
reaction to be viable full conversion must be achieved 
within this time frame.  Efforts to improve upon the 
76 % conversion including enzyme redosing, GP 
concentration variation and dosing, failed to deliver 
and the lack of full conversion on this larger batch scale 
was attributed to an equilibrium affect between GP and 
IP. Thus, it was concluded that the batch reaction 
would not prove viable for scale up of the process given 
the requirements defined at the outset.  
Conducting the biocatalysis in-flow presents many 
advantages over an in-batch system.
17
  In general, flow 
systems are more readily amenable to scale up than 
batch reaction processes.  Immobilisation of enzymes 
tends to improve their stability and aids enzyme 
recycling.  Additionally, product purification is further 
simplified with high conversion rates. The use of a flow 
system for TbINO1 is particularly attractive because it 
would resolve many of the issues encountered within 
batch process, in other words an equilibrium between 
substrate and product that would be detrimental 
would not be encountered. An immobilized TbINO1 
system set up that passes a low concentration of GP (1) 
at an optimal flow rate would ensure full conversion to 
IP (2) and overcome any issues associated with 
unfavourable product inhibition at equilibrium.  Once 
protein activity drops the reaction can be stopped and 
fractions containing only fully converted product can 
be collated for isolation.   
In these proof of concept studies, our recombinant 
TbINO1 was immobilized directly on a Ni
2+
-charged 
IMAC Sepharose
TM
 Fast Flow 6 column taking 
advantage of the C-terminal hexa His-tag. This resin, 
designed for protein purification though not optimal, 
has a loading capacity of up to 40 mg mL
-1
 of resin and 
provided a suitable enzyme support to perform 
preliminary studies. Initially a 1 mL column was loaded 
with purified TbINO1 by passing a solution at 25 mL h
-1
.  
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Figure 1 – Reaction set up. The TbINO1 loaded Ni
2+
-charged column 
was placed within a column oven to enable the reaction to be 
conducted at a constant 37 °C, and a peristaltic pump was used to 
control the movement of liquid through the system. 
A reaction solution containing 5 mM GP (1), 2 mM 
NAD
+
, 1 mM β-mercaptoethanol and 50 mM 
ammonium bicarbonate (pH 8.5) could then be passed 
through the system (Figure 1). The immobilized TbINO1 
was able to achieve an 81 % conversion in one pass at a 
flow rate of 2.5 mL hr
-1
 at 37 °C. The product was 
collected and acidified to pH <2 using concentrated 
hydrochloric acid, and following lyophilisation 
furnished IP, in its free acid form, as a white solid 
containing traces of NAD
+
/NADH. Dissolution in MeOH 
and filtration to remove the sparingly soluble 
NAD/NADH, followed by concentration gave the final 
product. However initial attempts to chemically modify 
the IP (2) were hampered by Ni2+-ions that had leached 
from the immobilised TbINO1 column.  This issue was 
resolved by the incorporation of a Ni
2+
-free column to 
scavenge leached Ni
2+
 ions. 
Following this initial success the stationary phase 
volume was increased to a 5 mL column to 
accommodate additional TbINO1 (up to 200 mg 
enzyme) to allow for a higher concentration of GP (1) 
to be processed under flow conditions and enable 
reaction monitoring via 
1
H NMR analysis. A reaction 
solution containing 18 mM GP (1), 1 mM NAD
+
, 1 mM 
β-mercaptoethanol and 50 mM ammonium 
bicarbonate (pH 8.5) can be passed through the system 
and achieve full conversion to IP (2) in one pass.  After 
36 hours the TbINO1 begins to significantly lose activity 
and was unable to fully convert the substrate (Figure 
2).  At this flow rate, and amount of enzyme (~200 mg), 
the system produced 420 mg of IP (2) in 36 hours.  The 
increased level of conversion in the flow system can be 
attributed to the increased amount of enzyme 
immobilized on the Sephadex support avoiding the 
problems of protein denaturation and co-factor 
decomposition which plagued the homogeneuous 
batch reaction variant.  Furthermore the lack of newly 
formed product (IP) interacting with the enzyme 
allowing an unfavourable equilibrium between GP and 
IP is significantly reduced, thus, near full conversion is 
achieved under flow conditions. 
Further processing and chemical derivatisation of L- 
myo-inositol-1-phosphate (2) 
Having established access to IP (2) we sought to 
explore its utility as a potential starting material in 
chemical synthesis. Our first priority was to effectively 
cap the sensitive phosphate moiety in 2. Not 
unsurprisingly there is little precedent for this 
transformation, however Griffin et al. used 
diazomethane for the selective methylation of simpler 
phosphates over alcohols.
18
 Following this precedent 
we opted for benzylation of the phosphate with 
phenyldiazomethane (Scheme 2). Thus, treatment of a 
high dilution solution of IP (2) in MeOH with freshly 
prepared ethereal phenyldiazomethane provide the 
bis-benzyl phosphate ester derivative 4 in 97% yield as 
a colourless solid after lyophilisation. 
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Figure 2 – Reaction progress monitored by 
1
H NMR spectroscopy. 
Reaction was conducted at 37 °C with a flow rate of 2.5 mL h
-1
 and 
the solution contained 18 mM GP (1), 1 mM NAD
+
, 1 mM β-
mercaptoethanol and 50 mM ammonium bicarbonate (pH 8.5).  A: 0 
to 20 h fractions, B: 20 to 30 h fraction, C: 30 to 40 h fraction.  
 
 
Scheme 2 – Selective phosphate benzylation using 
phenyldiazomethane. 
In order to demonstrate the viability of 4 as a building 
block for the synthesis of inositol derivatives we 
identified the pentaacetate 5 as suitable protected 
inositol intermediate, as shown in Scheme 3. This 
intermediate in either of its enantiomeric forms has 
been used in the synthesis of mycothiol 6 by 
Steenkamp et al.,
19
 and in the preparation of 
biotinylated chemical probes 7 by Otsuka et al.
20
 
Mycothiol is the major low molecular weight thiol used 
in most actinomycetes cells to reduce toxic oxidants 
and maintain an intracellular reducing environment.
21-
24
  Mycobacterium tuberculosis, contains some of the 
highest levels of mycothiol,
19
 and it is hypothesized that 
this organism could become vulnerable to therapeutics 
and other stress factors if the biosynthesis or functions 
of mycothiol are interrupted.
25
 Therefore, mycothiol 
and analogues thereof are important targets that could 
lead to urgently required novel therapeutic treatments 
for tuberculosis.
26
  
Synthetic routes to mycothiol (6) and derivatives 
adhere to similar synthetic strategies (Scheme 3) 
involving a protected cysteine (8), a glucosamine donor 
(9) and an enantiopure myo-inositol acceptor, such as 
ent-5 or 10. Synthetic routes have relied upon classical 
manipulations of myo-inositol with the shortest route 
to date of ent-5 requiring seven steps proceeding with 
a 7% overall yield.
19
 From our dibenzylated phosphate 
derivative 4 we sought to rapidly access the 
pentacetate 5 (Scheme 4),27 which could be used in the 
synthesis of an unnatural analogue (11) and that has 
previously proven to be valuable in the study of 
mycothiol biosynthesis.
19
 
 
Scheme 3 – Applications of inositol pentaacetate 5 in synthesis.  
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Scheme 4 – Synthesis of inositol pentaacetate derivative 5. 
Starting with peracetylation with acetic anhydride, 
pyridine and DMAP at room temperature provided 12 
in a modest 27% yield (Scheme 4).
28
 The removal of the 
phosphate was now required and a variety of direct 
acid hydrolysis conditions were screened without 
success including aqueous HF and HCl/MeOH. To 
overcome this problem, the benzyl groups were 
removed by hydrogenolysis and the crude intermediate 
13 was treated directly with an acid phosphatase to 
produce desired alcohol 5.  This route produced the 
desired peracetylated inositol intermediate 5 in four 
steps and 21 % yield from L-myo-inositol 1-phosphate 
(2), an improvement over those present within the 
literature.
19,20,27 
Conclusions 
We have developed a novel biocatalytic flow process 
that can produce L-myo-inositol 1-phosphate (2) at a 
rate of roughly 12 mg h
-1
.  The recombinant TbINO1 is 
stable under the reaction conditions for roughly 36 
hours, allowing access to 430 mg of the highly desirable 
product in one preparation.  We have demonstrated 
the convenience of using enantiopure L-myo-inositol 1-
phosphate (2) as a starting point in the synthesis of 
myo-inositol derivatives, furnishing enantiomerically 
pure pentaacetate 5 in four steps, a vast improvement 
over literature methods.  We aim to achieve different 
protection patterns about the myo-inositol core, in 
order to gain access to and drastically reduce routes to 
other important myo-inositol derivatives.  The 
biocatalytic TbINO1 flow system is not fully optimised 
at this stage requiring further investigation to 
determine the best method to immobilise TbINO1 and 
will be reported on in due course. However these 
studies clearly demonstrate the potential of a 
biocatalytic approach in addressing the complexities of 
inositol synthesis. 
Experimental 
Materials and methods 
Trypanosoma brucei L-myo-Inositol 1-phosphate Synthase 
(TbINO1) Expression and Purification
11,14
  Recombinant expression 
of TbINO1 was conducted using the pET15b-TbINO1 construct 
within BL21 Rosetta (DE3) cells (Invitrogen).  TbINO1 was purified 
by Ni
2+
-affinity chromatography, eluted with an increasing step 
gradient of imidazole (10, 20, 50, 100, 250 and 400 mM) in 20 mM 
ammonium bicarbonate (pH 8.5) and 250 mM NaCl.  The His-tagged 
protein was dialysed against 20 mM ammonium bicarbonate (pH 
8.5), 50 mM NaCl and 5 mM DTT.  The resulting solution could be 
stored with 10 % glycerol at -80 °C for up to 6 months.  In a typical 
expression, 600 mg of TbINO1 was collected from 8 L of cell culture 
(75 mg L
-1
). 
 TbINO1 Immobilisation: Frozen pellets from 4 L of growth media 
were suspended in a lysis buffer of 20 mM ammonium bicarbonate 
(pH 8.5), 200 mM NaCl and 3 mM 2-mercaptoethanol.  Cells were 
lysed by sonication (7 x 20 second bursts, 40 second rests) and the 
supernatant cleared by centrifugation (40,000 rcf, 20 minutes, 4 °C).  
The supernatant was filtered (0.45 μm) prior to loading onto a 
freshly charged, new 5 mL Ni
2+
-Sepharose column.  The column was 
washed with 25 mL of a solution containing 10 mM imidazole, 50 
mM ammonium bicarbonate (pH 8.5) and 1 mM 2-mercaptoethanol 
to elute the unwanted cell extracts.  The column was finally washed 
with a solution containing 50 mM ammonium bicarbonate (pH 8.5) 
and 1 mM 2-mercaptoethanol, before fitting a Sepharose column in 
series that had been previously stripped of any Ni
2+
 ions by washing 
with 50 mM EDTA solution. 
L-myo-Inositol 1-phosphate (2). A solution containing 18 mM D-
glucose 6-phosphate (1), 1 mM NAD
+
, 50 mM ammonium 
bicarbonate (pH 8.5) and 1 mM 2-mercaptoethanol was passed 
through the previously prepared flow system at a rate of 2.5 mL h
-1
.  
25 mL fractions were collected and each fraction was separately 
acidified to pH <2 using concentrated HCl, before being lyophilised 
to produce crude L-myo-inositol 1-phosphate (2).  1H NMR was 
used to determine which fractions contained no D-glucose 6-
O
OH
OH
OH
OHHO
P
O
BnO
BnO
O
OAc
OAc
OAc
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P
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phosphate (1), which were combined and dissolved in methanol, 
filtered and concentrated under reduced pressure to yield L-myo-
inositol 1-phosphate (2, 341 mg).   -4.60 (c 1.00, H2O at pH 
9); IR (ATR) 3262, 3041, 2965, 2936, 1634, 1033, 999; 
1
H NMR (500 
MHz, D2O) δ 4.24 (1H, t, J = 2.8 Hz, H-2), 3.94 (1H, ddd, J = 9.8, 8.8, 
2.8 Hz, H-1), 3.73 (1H, t, J = 9.7 Hz, H-6), 3.63 (1H, t, J = 9.7 Hz, H-4), 
3.54 (1H, dd, J  = 10.0, 2.9 Hz, H-3) and 3.31 (1H, t, J = 9.4 Hz, H-5); 
13
C NMR (126 MHz, D2O) δ 75.7, 73.8, 72.2, 71.4 (d, J = 6.1 Hz), 71.1 
and 70.7; 
31
P NMR (202 MHz, D2O) δ -0.19; HRMS (ES
-
) Calc. for 
C6H12O9P [M-H]
-
 259.0224, found 259.0222. 
 
1-Bis(benzyloxy)phosphoryl-L-myo-inositol (4). To a stirred 
solution of L-myo-inositol 1-phosphate (2, 200 mg, 0.77 mmol) in 
methanol (600 mL) at 0 °C was added an excess of ethereal 
phenyldiazomethane solution (freshly prepared, 6 equivalents of 
hydrazide S2 used in preparation).  The reaction was stirred for 4 h 
at 0 °C before being quenched with acetic acid (0.50 mL) and stirred 
for a further 10 minutes.  The reaction was concentrated before 
being dissolved in water (100 mL) and washed with diethyl ether 
(100 mL x 3).  The water was removed by lyophilisation to yield 1-
bis(benzyloxy)phosphoryl-L-myo-inositol (4, 329 mg, 0.75 mmol, 
97 %) as a pale yellow solid.   +6.50 (c 0.10, H2O); IR (ATR) 
3323, 3134, 3035, 2808, 1402, 1010, 999; 
1
H NMR (500 MHz, CDCl3) 
δ 7.48-7.34 (m, 10H, H-Ar), 5.12-5.06 (m, 4H, H-7), 4.16-4.10 (m, 1H, 
H-1), 4.07 (t, J = 2.9 Hz, 1H, H-2), 3.76 (t, J = 9.7 Hz, 1H, H-6), 3.60 (t, 
J = 9.6 Hz, 1H, H-4), 3.40 (dd, J = 10.0, 2.8 Hz, 1H, H-3) and 3.25 (t, J 
= 9.5 Hz, 1H, H-5);
 13
C NMR (126 MHz, CDCl3) δ 135.1, 129.1, 128.8, 
128.4, 78.7, 73.6, 71.9, 70.8, 70.8, 70.7, 70.7, 70.6, 70.5, 70.4, 70.3; 
31
P NMR (202 MHz, CDCl3) δ -1.95; HRMS (ES
+
) Calc. for C20H26O9P 
[M+H]
+
 441.1309, found 441.1308 
 
2,3,4,5,6-Penta-O-acetyl 1-bis(benzyloxy)phosphoryl L-myo-
inositol (12). To a stirred suspension of 1-bis(benzyloxy)phosphoryl 
L-myo-inositol (4, 100 mg, 0.23 mmol, 1 equiv.) in pyridine (5 mL) 
was slowly added acetic anhydride (1.06 mL, 11.21 mmol, 50 equiv.) 
and 4-dimethylaminopyridine (3 mg, 0.02 mmol, 0.1 equiv.) at 0 °C.  
The reaction was stirred at this temperature for 10 minutes before 
being stirred at room temperature for 5 h.  The reaction was 
concentrated under reduced pressure and the residue dissolved in 
dichloromethane (10 mL).  The solution was washed with water (10 
mL), HCl solution (1 M, 2 x 10 mL), water (10 mL) and brine (10 mL) 
before being dried over magnesium sulfate, filtered and 
concentrated under reduced pressure.  The crude product was 
purified by column chromatography (silica gel, 50 % ethyl acetate in 
hexane) to yield 12 as a colourless oil (40 mg, 0.06 mmol, 27 %).  Rf  
0.35 (50 % ethyl acetate in hexane);  +13.0 (c 1.00, CHCl3); IR 
(ATR) 3036, 2965, 1749, 1210, 1009, 999; 
1
H NMR (500 MHz, CDCl3) 
δ 7.34-7.18 (10H, m, Ar), 5.66 (1H, t, J = 3.0 Hz, H-2), 5.46-5.36 (2H, 
m, H-6 and H-4), 5.03 (1H, t, J = 9.9 Hz, H-5), 5.98-4.83 (5H, m, H-3 
and 2 x CH2), 4.50 (1H, dt, J = 3.0, 9.8 Hz, H-1), 2.07 (3H, s, Ac-2), 
1.94 (3H, s, Ac-4), 1.93 (6H, s, Ac-3 and Ac-5) and 1.79 (3H, s, Ac-6); 
13
C NMR (126 MHz, CDCl3) δ 169.9, 169.7, 169.7, 169.7, 169.5, 
128.7, 128.7, 128.7, 128.6, 128.0, 128.0, 73.0 (d, J = 5.3 Hz), 70.7, 
70.0 (d, J = 5.0 Hz), 69.9 (d, J = 5.9 Hz), 69.6 (d, J = 5.7 Hz), 69.3, 68.9 
(d, J = 2.81 Hz), 68.5, 20.7, 20.6 and 20.5; 
31
P NMR (202 MHz, CDCl3) 
δ -1.76; HRMS (ES
+
) Calc. for C30H36O14P [M+H]
+
 651.1837, found 
651.1823. 
 
2,3,4,5,6-penta-O-acetyl L-myo-inositol (5). To a stirred solution of 
pentaacetate 12 (6.3 mg, 9.73 μmol) in ethyl acetate (3 mL) was 
added palladium on carbon (10 wt % loading, 10 mg, 0.09 mmol).  
The reaction was purged with hydrogen and left under a positive 
pressure of hydrogen with stirring overnight.  The reaction was 
filtered through Celite and washed through with ethyl acetate, 
before being concentrated under reduced pressure to provide 
intermediate 13 (4 mg) which was used directly.  The crude 
phosphate 13 (4 mg, 8.9 μmol) was taken up in a mixture of sodium 
acetate buffer (50 mM, pH 5.2, 860 μL) and DMSO (40 μL) before 
lyophilised acid phosphatase (from potato, 3.3 Umg
-1
, 1 mg) was 
added and the reaction incubated with shaking at 37 °C overnight.  
The product was extracted into ethyl acetate (1 mL x 5) before 
being concentrated under reduced pressure to yield 5 (3 mg, 7.7 
μmol, 79 % over 2 steps).  Rf  0.56 (10 % methanol in DCM);  
+3.0 (c 0.2, CHCl3) [lit
27
 +8.7 (c 1.6, CHCl3)]; 
1
H NMR (500 MHz, 
CDCl3) δ 5.62 (1H, t, J = 3.0 Hz, H-2), 5.48 (1H, t, J = 10.2 Hz, H-4), 
5.33 (1H, t, J = 10.0 Hz, H-6), 5.17 (1H, t, J = 9.8 Hz, H-5), 4.99 (1H, 
dd, J = 10.6, 2.8 Hz, H-3), 3.91 (1H, dd, J = 10.1, 3.0 Hz, H-1), 2.24 
(3H, s, Ac), 2.12 (3H, s, Ac), 2.05 (3H, s Ac), 2.04 (3H, s, Ac) and 2.02 
(3H, s, Ac); 
13
C NMR (126 MHz, CDCl3) δ 171.1, 170.3, 169.9, 169.8, 
169.8, 72.5, 70.7, 70.5, 69.4, 69.1, 69.0, 20.9, 20.8, 20.6, 20.6 and 
20.6. 
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Immobilized TbINO1 produces >400 mg of chiral inositol 1-phosphate in biocatalytic 
flow process. 
O
OH
(HO)2OPO OH
OH
HO OHHO
OH
HO
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OH
glucose 6-phosphate L-myo-inositol-1-phosphate
> 400 mg in flow
immobilized
TbINO1
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